Exome Asset Management LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$153.0M2026 Q3
Positions55
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.2%
What Changed This Quarter?
Top Holdings
GH
Guardant Health
7.9%
TGTX
TG Therapeutics
6.8%
ABVX
Abivax S.A.
5.9%
PRAX
Praxis Precision Medicines
5.6%
COGT
Cogent Biosciences
4.4%
LLY
Eli Lilly
4.2%
NTRA
Natera
3.7%
VERA
Vera Therapeutics
3.4%
New / Increased
9 new · 17 increased
CMPSNEW
Compass Pathways
1.2%
CLDXNEW
Celldex Therapeutics
1.2%
MRKNEW
Merck
1.2%
PVLANEW
Palvella Therapeutics Inc
0.7%
RAPPNEW
Rapport Therapeutics
0.6%
ABVX
Abivax
5.9%
+93.9%
VKTX
Viking Therapeutics
3.1%
+208.2%
NKTR
Nektar Therapeutics
2.9%
+228.8%
Reduced / Exited
9 reduced · 6 sold out
TXG
10X Genomics
1.8%
-70.7%
QURE
Uniqure
0.3%
-77.4%
GKOS
Glaukos
1.2%
-45.3%
UNH
UnitedHealth
1.4%
-40.7%
Adagene
Adagene
0.1%
-89.2%
AGIOEXIT
Agios Pharmaceuticals
1.6%
CBIOEXIT
Crescent Biopharma
1.4%
AZNEXIT
AstraZeneca
1.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.